| Anti-CCP antibodies predict progression of palindromic rheumatism to rheumatoid arthritis |
|
Ji-Young Kim, Sung-Hoon Park, Seong-Kyu Kim, Sang-Gyung Kim, Im-Hee Shin, Jung-Yoon Choe |
|
|
| 재발성 류마티즘의 예후인자로서의 항 CCP 항체의 유용성 |
|
김지영 &#; 박성훈 &#; 김성규 &#; 김상경 &#; 신임희 &#; 최정윤, Sung-Hoon Park, Seong-Kyu Kim, Sang-Gyung Kim, Im-Hee Shin, Jung-Yoon Choe |
|
|
|
|
|
|
| Abstract |
Background/Aims
Palindromic rheumatism (PR) is an episodic arthropathy that may precede typical rheumatoid arthritis
(RA). The objective of this study was to determine whether anti-cyclic citrullinated peptide (anti-CCP) antibodies in
patients with PR contribute to the progression to RA.
Methods
The study group included 115 patients who were initially diagnosed with PR. Baseline serum samples were
stored and analyzed for the presence of anti-CCP antibodies, APF, and RF or for anti-CCP antibodies and HLA-DR4. A
multiple logistic regression analysis was used to identify predictive factors for progression to RA.
Results
The anti-CCP antibodies APF and RF were found in 33.3%, 28.9%, and 35.7% of the 115 patients with PR,
and 36 (31.3%) of these patients eventually progressed to RA. Comparing the risk factors for patients who progressed to
RA (31.3%) and those who did not (68.7%), only the presence of anti-CCP antibodies was found to affect progression to
RA (95% CI for OR, 0.0001-0.114; p<0.001). HLA-DR4-positivity was noted in 40% of the patients with PR, although
it did not affect progression to RA and was not significantly associated with the presence of anti-CCP antibodies.
Conclusions
Anti-CCP antibodies are found more frequently in patients with PR who eventually progress to RA.
Therefore, anti-CCP antibody testing of patients with PR may facilitate prediction of progression to RA. (Korean J Med
76:193-198, 2009) |
| Key Words:
Palindromic Rheumatism; Anti-CCP antibody |
|
PDF Links
Full text via DOI
Download Citation
